The making of South Korea's COVID-19 test success. IES Policy Brief Issue 2020/04 - April 2020 by Pardo, Ramon Pacheco
æPolicy  brief
by Ramon Pacheco Pardo
At least 120 countries have asked South Korea 
for COVID-19 test kits and other materials to 
fight against the ongoing coronavirus pandemic. 
South Korean biotech firms are shipping the 
kits everywhere from Europe and the United 
States to the Middle East and Southeast Asia. 
Once the coronavirus crisis is over, policymakers 
across the world will look at South Korea and ask 
themselves how they can replicate its success in 
quickly developing and manufacturing hundreds 
of thousands of reliable test kits. They should 
skip Seoul, and head straight to Daejeon instead.
South Korea’s fifth largest city lies a 50-minute 
high-speed train ride from the capital. It is home 
to Daedeok Innopolis. Not many outside of South 
Korea have heard of the country’s main R&D 
cluster. But it is the cradle of South Korea’s biotech.
In 1973, Park Chung-hee had the vision, and 
craziness, to establish KAIST, South Korea’s answer 
to MIT. Today it is one the top under 50 universities 
in the world, as per the QS World University 
rankings. Out of KAIST grew Daedeok Innopolis, 
home to over 230 government and corporate 
research institutes and educational institutions. 
This includes the Korea Research Institute of 
Bioscience and Biotechnology (KRIBB). Established 
in 1985, KRIBB covers all aspects of basic and 
applied research. It has strong synergies with 
KAIST and other research institutions across 
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Daedeok Innopolis – as well as with other institutes 
in South Korea and across the world. KRIBB 
arguably is the country’s biotech jewel in the crown.
Awash with government money, KRIBB conducts 
the type of basic science research that even the 
most profitable chaebol balk at. It places bets on 
which sectors to develop. KRIBB, for example, 
hosts the Viral Infectious Disease Research Center 
and the BioNano Health Guard Research Center. 
They are two important pillars of South Korea’s 
pandemic research, detection and monitoring.
At least 120 countries have asked South Korea 
for COVID-19 test kits and other materials to fight 
against the ongoing coronavirus pandemic. 
South Korean biotech firms are shipping the 
kits everywhere from Europe and the United 
States to the Middle East and Southeast Asia. 
The secret to South Korea’s test development 
and manufacturing success lies in Daejeon. 
This city is home to Daedeok Innopolis, 
South Korea’s main R&D cluster, including for 
biotech. Developed since the 1990s, South 
Korea’s biotech industry is a textbook case 
of the country’s industrial policy. It is based 
on two pillars: public-private cooperation 
and continuity across administrations. 
This is what Daedeok Innopolis and South 
Korea’s COVID-19 test success embody. 
The Making of South Korea’s COVID-19 
Test Success
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South Korea, along with fellow newly developed 
East Asian countries Singapore and Taiwan, 
decided to bet on becoming a global biotech leader 
in the 1990s. And it was a bet. South Korea had 
become rich by manufacturing cheaper and better 
products that others had invented. That model 
was not suitable for a country with increasingly 
expensive workers. South Korea had to compete 
at the technological frontier. It had to innovate. 
Biotech was one of the areas that the government 
and the private sector decided to prioritize.
South Korea is said to be hopelessly divided 
between liberals and conservatives. This isn’t true 
when it comes to many aspects of industrial policy 
and economic policy-making though. Following 
from the Asian Financial Crisis, Kim Dae-jung, South 
Korea’s first-ever liberal president, had no qualms 
to double down on his conservative predecessors’ 
push to make the country a leader in biotech.
Kim’s government realized that Korea had the 
necessary infrastructure, but did it have the 
necessary brains? His government launched 
Brain Korea 21 (BK21) in 1999. Rebranded 
BrainKorea21Plus, it has survived three liberal and 
two conservative administrations. Hundreds 
of billions of US dollars have been spent on 
training the next generation of South Korean 
innovators, with a focus on the natural and 
applied sciences, as well as engineering.
From the beginning, Seoul had the intention 
to make biotech a pillar of South Korea’s 
export-oriented economy. In other words, 
commercialization was key. The Kim government 
even set up BioValley in San Diego in 2002. The 
goal was to use government money to facilitate 
private sector exports by building infrastructure 
and providing below market or free leases to 
South Korean firms trying to crack the U.S. market.
By the mid-2000s, however, South Korea seemed 
to had fail. It was not in the same league as the 
United States, neighboring Japan or European 
powerhouses France, Germany and the United 
Kingdom. South Korea’s biotech firm were having 
trouble becoming internationally competitive.
The Global Financial Crisis helped to give new 
impetus to South Korea’s biotech push. The 
Lee Myung-bak government launched the 577 
initiative to foster ‘high risk, high return’ sectors 
such as nanotechnology, brain research and, 
certainly, biotech. Funding increased. Seoul also 
introduced policies to bring foreign researchers 
to universities and research institutes.
Today, OECD data indicates that South Korea is 
one of the global leader’s in the biotech sector. 
When combining R&D spending, number of 
patents and number of firms, only the United 
States and Japan can compete with South Korea.
The MERS outbreak of 2015, however, laid 
bare one of the inadequacies of South Korea’s 
approach to biotech. In short, it was unsuited to 
the manufacturing of the necessary products in 
times of crisis. There were too many regulatory 
loopholes for manufacturers to jump. With 
38 casualties, South Korea had the second 
largest number of deaths from MERS. The 
minister of Health and Welfare lost his job.
Reforms brought forward by the Park Geun-hye 
and Moon Jae-in governments allowed biotech 
firms to obtain fast-tracked regulatory approval 
for test kits when the COVID-19 pandemic broke 
out. Approval of new products can take up to 
one year and a half. Companies have received it 
within a week during the current pandemic. ‘Test, 
test, test’ has only been possible by the mass 
production of test kits. Without regulatory reforms, 
South Korea would have wasted precious weeks, 
or perhaps even months, to start producing them.
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Certainly, some of the firms now manufacturing 
and exporting test kits are based in Seoul or 
nearby cities like Suwon. Similar biotech firms 
are based in Pangyo and Bundang, also close to 
Seoul. After all, many scientists and researchers 
also prefer to live in South Korea’s economic 
and cultural heart. And Seoul’s universities also 
have many strengths in the area of biotech. 
Especially Seoul National University, which can 
match KAIST in many areas of biotech research.
But South Korea’s key biotech cluster is in 
Daejeon. Its roots can be traced back to almost 
50 years ago. The test kits ubiquitous in 
South Korea and increasingly across different 
parts of the world were first envisaged there.
South Korea’s success in test development and 
manufacturing is underpinned by two pillars of 
its industrial policy: public-private cooperation 
and continuity across administrations. 
This is what Daedeok Innopolis embodies.
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